Drug Profile

RCD 405

Alternative Names: RCD-405

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arcede Pharma
Class Anti-inflammatories; Antiasthmatics; Bronchodilators
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

29 May 2025 Iconovo plans a clinical trial for Chronic obstructive pulmonary disease
07 Sep 2024 Pharmacodynamics data from preclinical studies presented at the 34^thAnnual Congress of the European Respiratory Society (ERS-2024)
16 Nov 2023 Adverse events data from preclinical studies in Chronic obstructive pulmonary disease released by Arcede Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com